Group 1 - Company Nanmo Bio reported a revenue of approximately 303 million yuan for the first three quarters of 2025, representing a year-on-year increase of 14.29% [1] - The net profit attributable to shareholders of the listed company was approximately 26.76 million yuan, with a basic earnings per share of 0.34 yuan [1] - As of the report date, the market capitalization of Nanmo Bio was 3.6 billion yuan [2] Group 2 - The A-share market has surpassed 4000 points, marking a significant resurgence after a decade of stagnation, with technology leading the market's transformation [2] - A new "slow bull" market pattern is emerging, indicating a shift in market dynamics [2]

Financial Performance - The company's operating revenue for the third quarter reached ¥106,937,671.62, representing a year-on-year increase of 21.52%[3] - The total profit for the third quarter was ¥8,149,982.96, with a net profit attributable to shareholders of ¥8,597,530.11[3] - Year-to-date revenue as of the reporting period was ¥302,700,815.36, showing a 14.29% increase compared to the same period last year[3] - The company reported a significant increase in net profit attributable to shareholders for the quarter, with a year-on-year growth of 242.07%[9] - Total operating revenue for the first three quarters of 2025 reached ¥302.70 million, an increase of 14.26% compared to ¥264.85 million in the same period of 2024[18] - Operating profit for the first three quarters of 2025 was ¥26.56 million, a significant turnaround from a loss of ¥20.81 million in the same period of 2024[19] - Net profit for the first three quarters of 2025 was ¥26.76 million, compared to a net loss of ¥15.20 million in the same period of 2024[19] - Basic and diluted earnings per share for the first three quarters of 2025 were both ¥0.34, recovering from a loss of ¥0.20 per share in the same period of 2024[19] Research and Development - Research and development expenses totaled ¥21,128,375.40 for the quarter, accounting for 19.76% of operating revenue, a decrease of 1.18 percentage points year-on-year[4] - Research and development expenses increased to ¥62.72 million, up from ¥57.23 million, indicating a focus on innovation[18] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥19,641,082.96[3] - The company's cash and cash equivalents as of September 30, 2025, amount to ¥123,995,787.94, down from ¥200,731,445.41 at the end of 2024[14] - Total assets as of the reporting period were ¥1,899,214,539.20, reflecting a decrease of 1.56% from the end of the previous year[4] - Total assets decreased to ¥1,899.21 million from ¥1,929.36 million, a decline of 1.56%[16] - The company's cash flow from operating activities is yet to be detailed in the provided data, indicating potential areas for future reporting[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 6,687[12] - The largest shareholder, Shanghai Dish Consulting Co., Ltd., holds 27,771,000 shares, representing 35.62% of total shares[12] - The company has not reported any changes in the top 10 shareholders due to margin trading activities[14] - There are no significant related party transactions or actions among shareholders reported[13] - The company has not received any notifications regarding other shareholders having related party relationships or acting in concert[13] Government and Market Strategy - The company expects to continue strengthening its domestic market presence, contributing to revenue growth and cost control measures[9] - Government subsidies received during the year have increased compared to the previous year, positively impacting the financial results[9] - The company is focusing on market expansion and new product development, as indicated by the increase in R&D expenses[18] Liabilities and Costs - Total liabilities decreased to ¥197.12 million from ¥246.36 million, a reduction of 20%[16] - Total operating costs decreased to ¥285.43 million from ¥296.66 million, reflecting a reduction of 3.93%[18] Cash Flow Activities - Cash inflow from operating activities totaled $283,031,576.85, an increase from $250,814,892.48 in the previous period, reflecting a growth of approximately 12.8%[22] - Net cash flow from operating activities improved to $19,641,082.96, compared to a negative cash flow of $6,582,776.74 in the prior period[22] - Cash inflow from investment activities reached $2,351,249,376.76, significantly higher than $1,663,787,664.49, marking an increase of about 41.3%[22] - Net cash flow from investment activities was negative at -$81,472,532.88, a decline from a positive cash flow of $54,334,669.66 previously[22] - Cash outflow from financing activities amounted to $14,702,993.05, down from $77,741,015.51, indicating a reduction of approximately 81.1%[23] - The net increase in cash and cash equivalents was -$77,207,060.17, compared to -$29,444,646.47 in the previous period[23] - The ending balance of cash and cash equivalents stood at $119,007,785.43, up from $68,158,274.93 at the end of the previous period[23] - The company reported a cash inflow of $2,351,180,132.49 from the recovery of investments, compared to $1,663,733,736.39 previously, reflecting a growth of approximately 41.4%[22] - Payments to employees increased to $143,887,427.60 from $136,133,446.55, representing a rise of about 5.1%[22] Accounting Standards - The company did not execute any new accounting standards or interpretations for the year 2025[24]

证券代码：688265 证券简称：南模生物 公告编号：2025-067 公司网址：https://www.modelorg.com/ 投资者邮箱：ir@modelorg.com 上海南方模式生物科技股份有限公司 关于变更主要办公地址的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海南方模式生物科技股份有限公司（以下简称"公司"）因内部管理需 要，于近日对主要办公地址进行了调整，为方便投资者与公司沟通和交流，现 将公司主要办公地址和投资者联系方式相关情况公告如下： 一、公司联系方式变更情况 | 主要办公地址 | 上海市浦东新区琥珀路 | | | 63 | 上海市浦东新区琥珀路 63 | | --- | --- | --- | --- | --- | --- | | 联系方式 | | 弄 号 1 6 | 变更前 层 | | 变更后 弄 号 1 | 二、公司最新联系方式 公司除主要办公地址变更外，投资者热线等联系方式未发生变化，具体联 系方式如下： 投资者热线：021-58120591 公司传真：021-2079115 ...

Core Viewpoint - Nanmo Biology (688265.SH) is currently experiencing a decline in stock price, with a closing price of 47.49 yuan and a drop of 4.06%, indicating a state of being below its initial public offering price [1] Group 1: Company Overview - Nanmo Biology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 28, 2021, with an issuance of 19.49 million shares at a price of 84.62 yuan per share [1] - The stock reached a peak price of 82.00 yuan on its first trading day, which remains the highest price since its listing [1] Group 2: Fundraising and Financials - The total amount raised from the initial public offering (IPO) was 1.649 billion yuan, with a net amount of 1.468 billion yuan after deducting issuance costs [1] - The net fundraising amount exceeded the original plan by 1.068 billion yuan, as the company initially aimed to raise 400 million yuan for various projects [1] - The total issuance costs amounted to 181 million yuan, with underwriting and sponsorship fees accounting for 158 million yuan [1] Group 3: Planned Use of Funds - The funds raised are intended for several projects, including the establishment of a biological research base, construction of a genetically modified model resource library, development of humanized antibody mouse models, and a drug efficacy platform based on genetically modified animal models, as well as to supplement working capital [1]

Group 1 - The core point of the news is that Nanmo Biological experienced a decline of 5.05% in its stock price, reaching 47.00 yuan per share, with a trading volume of 59.08 million yuan and a turnover rate of 1.56%, resulting in a total market capitalization of 3.664 billion yuan [1] - Nanmo Biological, established on September 20, 2000, and listed on December 28, 2021, specializes in the research, production, and sales of genetically modified animal models and related technical services [1] - The revenue composition of Nanmo Biological includes standardized models (48.34%), model technical services (21.92%), model breeding (19.50%), customized models (9.34%), and other supplementary services (0.91%) [1] Group 2 - Among the top ten circulating shareholders of Nanmo Biological, a fund under Rongtong Fund holds a position, having reduced its holdings by 150,000 shares in the second quarter, now holding 800,000 shares, which accounts for 1.03% of the circulating shares [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund (000727) was established on December 25, 2014, with a latest scale of 1.816 billion yuan, achieving a year-to-date return of 16.1% and a one-year return of 12.65% [2] - The fund manager, Wan Minyuan, has a tenure of 9 years and 65 days, with the fund's total asset size at 5.957 billion yuan, achieving a best return of 146.05% and a worst return of -20.75% during his tenure [3]

Core Viewpoint - The company, Shanghai Southern Model Biological Technology Co., Ltd., has announced the progress of its share repurchase and subsequent reduction plan, indicating a commitment to maintaining shareholder value and adhering to regulatory requirements [1][2]. Summary by Sections Share Repurchase Overview - The company repurchased a total of 788,912 shares from February 23, 2024, to May 22, 2024, which accounts for 1.0119% of its total share capital. The repurchased shares are intended to maintain company value and shareholder rights, with plans to sell them within 12 months after the announcement of the repurchase results [1]. Reduction Plan Progress - On August 29, 2025, the company disclosed a plan to reduce up to 779,635 shares (not exceeding 1% of total share capital) through centralized bidding within three months following the announcement. The reduction will be adjusted if there are changes in share capital due to dividends or other corporate actions [2][3]. Implementation Status of Reduction Plan - As of September 30, 2025, the company has not yet reduced any of the repurchased shares. The company is required to disclose the progress of the reduction plan within the first three trading days of each month [4]. Other Relevant Matters - There are no significant changes to the previously disclosed reduction plan, and no major corporate actions such as high bonus shares or mergers have been announced during the reduction period [3][4].

回购股份的基本情况 证券代码：688265 证券简称：南模生物 公告编号：2025-066 上海南方模式生物科技股份有限公司 关于回购股份集中竞价减持股份进展公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 上海南方模式生物科技股份有限公司（以下简称"公司"）于 2024 年 2 月 23 日至 2024 年 5 月 22 日期间通过集中竞价交易方式累计回购股份 788,912 股，占 公司总股本的 1.0119%。前述回购的股份拟用于维护公司价值及股东权益，将在 披露回购实施结果公告（即 2024 年 5 月 23 日）12 个月后采用集中竞价的方式 出售，并在披露股份回购实施结果公告日后 3 年内完成转让；若公司未能在上述 期限内完成转让，尚未转让的已回购股份将予以注销。 减持计划的进展情况 2025 年 8 月 29 日，公司在上海证券交易所网站（www.sse.com.cn）披露了 《关于回购股份集中竞价减持股份计划公告》（公告编号：2025-054），公司计划 按照市场价格，通过集 ...

Core Viewpoint - The internal conflicts within the board of directors of Nanmo Biology have drawn significant attention from the capital market, particularly following the recent management changes and the ongoing disagreements among board members [1][4]. Group 1: Management Changes - Nanmo Biology announced the re-election of Fei Jian as chairman and the appointment of Zhang Chunming as general manager and CFO, marking a significant shift in the company's core management [1][3]. - The board's recent meetings revealed multiple dissenting and abstaining votes regarding the election of committee members and the appointment of the new general manager, indicating persistent internal divisions [2][3]. Group 2: Board Dynamics - The newly formed board committees are led by members nominated by major shareholders, with Fei Jian holding significant influence over strategic decisions [2]. - The absence of former general manager Wang Mingjun from the committee member list suggests a decline in his influence within the company, as he opposed several key proposals during the board meetings [2][3]. Group 3: Historical Context - Fei Jian and Wang Mingjun, once aligned as partners, have recently experienced a breakdown in their collaborative relationship, which has become evident in board decisions and strategic discussions [3][4]. - The dissolution of their previously unified action agreement has led to increased conflicts during board elections and strategic planning, raising concerns about the stability of control within Nanmo Biology [4]. Group 4: Financial Performance - Nanmo Biology has shown revenue growth, with a reported revenue of 196 million yuan in the first half of the year, reflecting a year-on-year increase of 10.69%, while the net profit attributable to shareholders rose by 298.69% to 18.17 million yuan [5]. - Despite the revenue growth, the company has faced challenges with profitability, as indicated by negative net profits for three consecutive years from 2022 to 2024 [5].

费俭通过上海砥石、上海璞钰企业管理咨询合伙企业（有限合伙）间接合计持有南模生物股份841.34万 股，持股比例为 10.79%。 9月30日，南模生物公告，公司选举费俭为董事长，并选举第四届董事会各专门委员会委员。 此外，南模生物聘任张春明为总经理兼财务总监，孙瑞林、冯东晓为副总经理，祖婷为证券事务代表， 并指定董事长费俭代行董事会秘书职责，直至公司聘任新的董事会秘书。 在此之前，南模生物董事长兼创始人费俭与总经理王明俊之间存在分歧。两人同为控股股东上海砥石的 股东，但已于4月27日公告解除一致行动关系。 王明俊通过上海砥石、上海砥君企业管理咨询合伙企业（有限合伙）间接合计持有南模生物股份796.6 万股，持股比例为10.22%。（智通财经李科文） ...

Core Viewpoint - The recent board meeting of Nanmo Biology (688265.SH) marked a significant management reshuffle, with the company's actual controller Wang Mingjun not re-elected as general manager, highlighting internal governance issues and strategic conflicts within the company [1][12]. Group 1: Company Governance Issues - The dual-controller structure of Nanmo Biology, involving Chairman Fei Jian and General Manager Wang Mingjun, initially provided complementary strengths but has evolved into a source of governance deadlock and internal strife post-IPO [2][9]. - The internal conflicts have escalated, leading to public disputes over strategic decisions, such as the establishment of facilities in economically disadvantaged areas and IT infrastructure investments, which have adversely affected company performance [10][11]. Group 2: Business Development and Market Position - Nanmo Biology operates in the innovative drug industry, focusing on genetically modified animal models, particularly mice, which are essential for drug development processes [3][4]. - The company experienced a pivotal growth phase after the introduction of CRISPR technology in 2012, which allowed for the mass production of genetically engineered mouse models, significantly expanding market opportunities [4][5]. - Despite initial success and a successful IPO in December 2021, the company has faced ongoing losses and a declining stock price, exacerbated by internal conflicts and strategic misalignments [7][11]. Group 3: Recent Developments - The board's recent restructuring resulted in a new leadership team, with Zhang Chunming appointed as general manager, following the removal of Wang Mingjun, indicating a shift in control dynamics within the company [13][14]. - The ongoing internal strife has drawn regulatory scrutiny, with the Shanghai Stock Exchange issuing inquiries regarding the governance issues and the board's decision-making processes [1][12]. Group 4: Market Outlook - The market for genetically modified mice in China is projected to grow significantly, with a compound annual growth rate of 24% from 2019 to 2024, indicating potential future opportunities for Nanmo Biology if governance issues can be resolved [15][16].